Phase 1 two-part, randomized, double-blind, placebo controlled, dose-escalation study clinical trial of MF-300 in healthy adults
Latest Information Update: 05 Feb 2025
Price :
$35 *
At a glance
- Drugs MF 300 (Primary)
- Indications Sarcopenia
- Focus Adverse reactions
- 30 Jan 2025 Status changed from planning to recruiting.
- 30 Jan 2025 According to an Epirium Bio media release, company anticipates reporting topline results in the second half of 2025.
- 30 Jan 2025 According to an Epirium Bio media release, company announced that it has initiated dosing of healthy volunteers in its Phase 1 dose-escalation clinical trial of MF-300.